Top Markets
Coin of the day
Aeglea BioTherapeutics, Inc. Aeglea BioTherapeutics, Inc.

Aeglea BioTherapeutics, Inc.

AGLE
Classifica tra le azioni #23495
Aeglea BioTherapeutics, Inc. is a clinical-stage biotechnology firm dedicated... Aeglea BioTherapeutics, Inc. is a clinical-stage biotechnology firm dedicated to creating human enzyme therapies for rare metabolic diseases. Their leading candidate, pegzilarginase, a recombinant human Arginase 1, is currently in the pivotal Phase III PEACE trial to assess its safety and effectiveness for treating Arginase 1 deficiency. Furthermore, the company is developing AGLE-177, a polyethylene glycol modified enzyme, which is progressing through Phase I/II clinical trials for homocystinuria. Their early-stage pipeline includes AGLE-325 for cystinuria, along with other ongoing research initiatives. Founded in 2013, the company was initially known as Aeglea BioTherapeutics Holdings, LLC, changing its name to Aeglea BioTherapeutics, Inc. in March 2015. It is based in Austin, Texas.
Prezzo delle azioni
$19.30
Ultima sincronizzazione: 2023-12-26
Capitalizzazione di mercato
$72.77M
Variazione (1 giorno)
6.22%
Variazione (1 anno)
0.00%
Paese
US
Scambia Aeglea BioTherapeutics, Inc. (AGLE)

Categoria

Storico del prezzo dell'azione per Aeglea BioTherapeutics, Inc. (AGLE)
Prezzo di chiusura più alto: $17.81 il 2023-12-01

Prezzo di chiusura più basso: $240.00 il 2016-04-01
Storico del prezzo dell'azione di Aeglea BioTherapeutics, Inc. dal 2016 al 2026
Andamento annuale del prezzo dell'azione
Anno Performance
2023 80.43%
2022 -90.79%
2021 -48.55%
2020 6.06%
2019 3.25%
2018 49.19%
2017 -3.90%
2016 0.00%
Prezzo dell'azione per aziende simili o concorrenti
Azienda Prezzo dell'azione Variazione 1a% Il paese
$547.71 38.62%
US
$1.04K 58.06%
NL
$145.75 437.43%
US
$118.70 -15.60%
AU
$770.19 8.98%
CH